Tevogen Bio Holdings Inc.
0.6159+0.01 (+1.84%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · TVGN · USD
Key Stats
Market Cap
121.15MP/E (TTM)
-Basic EPS (TTM)
-0.19Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Tevogen Bio Holdings narrowed its Q2 operating loss to $5.4 million from $8.6 million a year earlier, thanks to lower research and development spending, while stock-based compensation remained a hefty drag at $3.2 million. For the first half, the net loss hit $15.9 million, or $0.09 per diluted share on 182.5 million shares, versus a $1.6 million profit last year boosted by one-time fair value gains—now absent, leaving operations firmly in the red. Cash dipped to $0.7 million by quarter-end, but a $4.4 million loan draw and $2.5 million in grants and contributions kept things afloat, with $24 million more available under the facility. No free cash flow disclosed in the 10-Q. Yet funding stays tight. Clinical trials wait on fresh capital.
8-K
CEO receives 8M RSUs
Tevogen Bio Holdings issued 8 million restricted stock units to CEO and Chairperson Dr. Ryan Saadi on June 27, 2025, boosting outstanding common shares to 193,693,433 as of July 10. These shares vest in four equal annual installments starting on the seventh anniversary, tied to continuous service, with full acceleration on death or disability. Other grantees receive vesting over three years from the fifth anniversary. This long-term incentive aligns leadership with sustained company performance, yet locks up liquidity for years.
8-K
ATM equity sales pact
Tevogen Bio Holdings inked a sales agreement on July 3, 2025, with A.G.P./Alliance Global Partners to offload up to $50 million in common stock via at-the-market offerings. This setup lets the biotech tap equity markets flexibly, using commercially reasonable efforts from the agent without sales mandates. The company can halt it anytime. Yet dilution looms for shareholders.
8-K
CEO funds HQ build-out
Tevogen Bio Holdings received a $500,000 cash infusion from CEO Ryan Saadi on June 30, 2025, earmarked for building out its new headquarters in Warren, New Jersey, and covering initial operating costs. This bolsters the biotech's infrastructure amid ongoing capital needs. Yet risks loom: additional funding may prove elusive.
8-K
Annual meeting elects directors
Tevogen Bio Holdings Inc. held its 2025 Annual Meeting on June 23, electing Jeffrey Feike and Dr. Curtis Patton as Class I directors for three-year terms, with strong support from 150 million shares each. Stockholders also ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025, passing overwhelmingly at 167 million votes for. Board continuity solidified. No other proposals surfaced.
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
ENGN
enGene Holdings Inc.
7.33-0.58
EVGN
Evogene Ltd.
1.28-0.03
GBIO
Generation Bio Co.
5.57-0.22
IMA
ImageneBio, Inc.
8.79+0.09
INAB
IN8bio, Inc.
2.00-0.10
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
MRKR
Marker Therapeutics, Inc.
0.97-0.04
PGEN
Precigen, Inc.
4.01-0.05
VIR
Vir Biotechnology, Inc.
5.91-0.52